Mirabella Financial Services LLP Sells 49,366 Shares of Stryker Co. (NYSE:SYK)

Mirabella Financial Services LLP cut its holdings in Stryker Co. (NYSE:SYK - Free Report) by 60.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 32,700 shares of the medical technology company's stock after selling 49,366 shares during the quarter. Mirabella Financial Services LLP's holdings in Stryker were worth $11,813,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Patrick M Sweeney & Associates Inc. raised its holdings in shares of Stryker by 1.5% in the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company's stock worth $793,000 after acquiring an additional 32 shares during the last quarter. Versant Capital Management Inc raised its stake in shares of Stryker by 4.0% in the second quarter. Versant Capital Management Inc now owns 864 shares of the medical technology company's stock worth $294,000 after purchasing an additional 33 shares during the last quarter. Stanley Laman Group Ltd. lifted its holdings in shares of Stryker by 4.6% in the second quarter. Stanley Laman Group Ltd. now owns 752 shares of the medical technology company's stock valued at $256,000 after purchasing an additional 33 shares in the last quarter. Plimoth Trust Co. LLC boosted its position in shares of Stryker by 0.3% during the second quarter. Plimoth Trust Co. LLC now owns 9,476 shares of the medical technology company's stock valued at $3,224,000 after buying an additional 33 shares during the last quarter. Finally, Grimes & Company Inc. grew its holdings in Stryker by 0.4% during the third quarter. Grimes & Company Inc. now owns 8,239 shares of the medical technology company's stock worth $2,977,000 after buying an additional 33 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

Shares of SYK stock traded down $0.22 during trading on Monday, reaching $384.63. 2,102,817 shares of the company's stock traded hands, compared to its average volume of 1,272,761. The company has a market capitalization of $146.63 billion, a P/E ratio of 41.25, a PEG ratio of 2.90 and a beta of 0.91. Stryker Co. has a 1 year low of $285.79 and a 1 year high of $398.20. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The firm's 50-day moving average is $366.20 and its 200 day moving average is $349.63.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the firm earned $2.46 EPS. Equities research analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Insider Transactions at Stryker

In other news, insider Viju Menon sold 600 shares of the business's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company's stock, valued at approximately $3,219,495. The trade was a 6.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. This trade represents a 42.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 67,381 shares of company stock worth $24,825,275. 5.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Wolfe Research started coverage on Stryker in a research note on Tuesday, September 10th. They set an "outperform" rating and a $405.00 price objective on the stock. Canaccord Genuity Group raised their price target on shares of Stryker from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. upped their price objective on shares of Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. Stifel Nicolaus dropped their target price on shares of Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a research report on Wednesday, July 31st. Finally, Truist Financial upped their target price on Stryker from $370.00 to $380.00 and gave the company a "hold" rating in a report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.